Loading clinical trials...
Loading clinical trials...
Quetiapine Augmentation of Prolonged Exposure (PE) Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury
A pilot study to evaluate feasibility for a full-scale merit application. Specifically, for veterans considering prolonged exposure (PE) therapy, following the model established by Foa et al, we need to establish safety, and feasibility of quetiapine compared to treatment as usual (TAU) which employs multiple medications commonly used for PTSD in the VA system.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
UT Health San Antonio
San Antonio, Texas, United States
Start Date
February 1, 2019
Primary Completion Date
April 29, 2022
Completion Date
October 17, 2022
Last Updated
May 9, 2023
28
ACTUAL participants
Quetiapine Fumarate
DRUG
Standard of care meducations
OTHER
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
NCT06947538
NCT07462312
NCT06516874
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions